#API Manufacturing,
Explore articles tagged with API Manufacturing,
Beyond APIs, Into Finished Formulations
HRV Pharma is expanding beyond APIs into finished formulations through its acquisition of a 100% equity stake in Germany-based Phatebo. The acquisition marks a significant step in HRV's growth, giving the company its first finished formulations business and a licensed operating presence in Germany, while opening new opportunities in the European pharmaceutical market.
Two Bets on Complex Molecules, One Asset Light Model
HRV Pharma is planning a ₹150 crore investment in peptides and high-potency APIs through a dedicated peptide programme and a joint venture focused on specialised oncology molecules. Both initiatives follow the company's asset-light model, retaining intellectual property, regulatory assets and commercial rights while working with specialist manufacturing partners.
Meet RIKO, Built From Seven Years of Pharma Decisions
HRV Pharma has launched RIKO, an AI-native pharmaceutical operating system built on more than seven years of industry decisions. Drawing on insights from a network of 50+ FDA and EU GMP certified partners and customers across 55 countries, RIKO brings together AI-driven reasoning to support pharmaceutical sourcing, risk assessment and supplier qualification.
Not a Capacity Problem, a Utilisation Problem
When Hari Kiran Chereddi founded HRV Pharma in 2016, he saw an opportunity to address underutilised pharmaceutical manufacturing capacity in India. In this ET Now interview, he explains HRV's asset-light model, its quality assurance systems across 53 sites, and its ambition to reach ₹1,000 crore while remaining debt free.
No Factory, ₹400 Crore Revenue: How HRV Made It Happen
How does HRV Pharma generate over ₹400 crore in revenue without owning a manufacturing plant? Discover its asset-light business model, network of 50+ US FDA and EU approved manufacturing partners, and growth to 700+ customers across 55 countries.